Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics

Drug and Alcohol Dependence

Volumn 125, Issue 3, 2012, Pages 260-266

  Tran, Bach Xuan ^a,b   Ohinmaa, Arto ^a,c   Duong, Anh Thuy ^d   Nguyen, Long Thanh ^d   Vu, Phu Xuan ^e   Mills, Steve ^f   Houston, Stan ^a   Jacobs, Philip ^a,c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HANOI MEDICAL UNIVERSITY   (Viet Nam)

^c INSTITUTE OF HEALTH ECONOMICS   (Canada)

^d MINISTRY OF HEALTH   (Viet Nam)

^e HANOI UNIVERSITY OF PUBLIC HEALTH   (Viet Nam)

^f FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Adherence; Antiretroviral treatment; Cost effectiveness; Directly observed therapy; HIV AIDS; Methadone

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; METHADONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG DEPENDENCE; FEMALE; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; METHADONE TREATMENT; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VIET NAM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ATTITUDE; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG USERS; EPIDEMICS; FEMALE; HEALTH SERVICES; HIV SEROPOSITIVITY; HUMANS; MALE; METHADONE; MODELS, STATISTICAL; MONTE CARLO METHOD; NARCOTICS; ODDS RATIO; OPIATE SUBSTITUTION TREATMENT; QUALITY-ADJUSTED LIFE YEARS; SUBSTANCE ABUSE, INTRAVENOUS; VIETNAM;

EID: 84866363432     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.02.021     Document Type: Article

References (48)

1. Alistar S.S., Owens D.K., Brandeau M.L. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011, 8:e1000423.
2. Andrew Briggs, Karl Claxton, Mark Sculpher Decision Modelling for Health Economic Evaluation 2006, Oxford University Press, USA.
3. Batkis M.F., Treisman G.J., Angelino A.F. Integrated opioid use disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agonist therapies. AIDS Patient Care STDS 2010, 24:15-22.
4. Bergenstrom A.M., Abdul-Quader A.S. Injection drug use, HIV and the current response in selected low-income and middle-income countries. AIDS 2010, 24(Suppl. 3):S20-S29.
5. Bruce R.D. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int. J. Drug Policy 2009, 21:122-124.
6. Doubilet P., Begg C.B., Weinstein M.C., Braun P., McNeil B.J. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med. Decis. Making 1985, 5:157-177.
7. Falster K., Choi J.Y., Donovan B., Duncombe C., Mulhall B., Sowden D., Zhou J., Law M.G. AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS 2009, 23:2323-2336.
8. Fischer B., Cruz M.F., Patra J., Rehm J. Predictors of methadone maintenance treatment utilization in a multisite cohort of illicit opioid users (OPICAN). J. Subst. Abuse Treat. 2008, 34:340-346.
9. Gardner E.M., Hullsiek K.H., Telzak E.E., Sharma S., Peng G., Burman W.J., MacArthur R.D., Chesney M., Friedland G., Mannheimer S.B. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 2010, 24:395-403.
10. General Statistics Office, 2010. GDP per capital, 2009. (accessed 26.06.11). http://www.gsogovvn.com/.
11. Health Policy Initiative, 2008. Costs Associated with Implementing an Opioid Substitution Therapy Program for IDUs in Viet Nam. http://wwwhealthpolicyinitiativecom/Publications/Documents/1078_1_Costs_Associated_with_OST_FINAL_accpdf.
12. Jelsma J., Maclean E., Hughes J., Tinise X., Darder M. An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS Care 2005, 17:579-588.
13. Jordan M.R., Bennett D.E., Bertagnolio S., Gilks C.F., Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir. Ther. 2008, 13(Suppl. 2):15-23.
14. Josefine Nilsson, Dina Vemming Oksen, 2010. Antiretroviral therapy adherence in Quang Ninh, Vietnam - Analyzing results on adherence from a randomized controlled trial. Bachelor Thesis Goteborgs University Full text: http://gupeaubguse/bitstream/2077/23157/1/gupea_2077_23157_1pdf.
15. Laufer F. Thresholds in cost-effectiveness analysis-more of the story. Value Health 2005, 8:86-87.
16. Lucas G.M., Mullen B.A., McCaul M.E., Weidle P.J., Hader S., Moore R.D. Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS 2007, 21:564-574.
17. Lucas G.M., Mullen B.A., Weidle P.J., Hader S., McCaul M.E., Moore R.D. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin. Infect. Dis. 2006, 42:1628-1635.
18. Lucas G.M., Weidle P.J., Hader S., Moore R.D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin. Infect. Dis. 2004, 38(Suppl. 5):S409-S413.
19. Mahy M., Lewden C., Brinkhof M.W., Dabis F., Tassie J.M., Souteyrand Y., Stover J. Derivation of parameters used in spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sex. Transm. Infect. 2010, 86(Suppl. 2):ii28-ii34.
20. Mathers B.M., Degenhardt L., Ali H., Wiessing L., Hickman M., Mattick R.P., Myers B., Ambekar A., Strathdee S.A. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010, 375:1014-1028.
21. May Myat W., Maek A.N.W., Phonrat B., Kiertiburanakul S., Sungkanuparph S. Virologic and Immunologic Outcomes of the second-line regimens of antiretroviral therapy among HIV-infected patients in Thailand. J. Int. Assoc. Physicians AIDS Care (Chic.) 2011, 10:57-63.
22. Mills E.J., Bakanda C., Birungi J., Mwesigwa R., Chan K., Ford N., Hogg R.S., Cooper C. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2010, 25:851-855.
23. Ministry of Health National HIV AIDS Care and Treatment Guidelines 2007, Medical Publishing House, Hanoi.
24. Ministry of Health National Strategy on HIV/AIDS Prevention and Control Towards 2010 2008, Medical Publishing House, Hanoi.
25. Ministry of Health The Annual Review of HIV/AIDS Control and Prevention in 2008 and Action Plan in 2009 2009, Medical Publishing House, Hanoi.
26. Ministry of Health National Guidelines on HIV/AIDS Diagnosis, Care and Treatment 2009, Medical Publishing House, Hanoi.
27. Ministry of Health 2009 Antiretroviral Therapy Cohort Assessment and HIV Drug Resistance Early Warning Indicators 2010, Medical Publishing House, Hanoi.
28. Ministry of Health Effectiveness Evaluation of the Pilot Program for Treatment of Opioid Dependence with Methadone in Hai Phong and Ho Chi Minh Cities 2010, Medical Publishing House, Hanoi.
29. Ministry of Health Report on Current Situation of the HIV Epidemics in Vietnam, from January 1, 2009 to December 12, 2009 2010, Medical Publishing House, Hanoi.
30. Murray C.J., Evans D.B., Acharya A., Baltussen R.M. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000, 9:235-251.
31. Nosyk B., Marsh D.C., Sun H., Schechter M.T., Anis A.H. Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. J. Subst. Abuse Treat. 2010, 39:22-31.
32. Philips Z., Bojke L., Sculpher M., Claxton K., Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006, 24:355-371.
33. Philips Z., Ginnelly L., Sculpher M., Claxton K., Golder S., Riemsma R., Woolacoot N., Glanville J. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol. Assess. 2004, 8. iii-iv, ix-xi, 1-158.
34. Ray M., Logan R., Sterne J.A., Hernadez-Diaz S., Robins J.M., Sabin C., Bansi L., van Sighem A., de Wolf F., Costagliola D., Lanoy E., Bucher H.C., von Wyl V., Esteve A., Casbona J., del Amo J., Moreno S., Justice A., Goulet J., Lodi S., Phillips A., Seng R., Meyer L., Perez-Hoyos S., Garcia de Olalla P., Hernan M.A. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010, 24:123-137.
35. Roux P., Carrieri M.P., Cohen J., Ravaux I., Poizot-Martin I., Dellamonica P., Spire B. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin. Infect. Dis 2009, 49:1433-1440.
36. Roux P., Carrieri M.P., Villes V., Dellamonica P., Poizot-Martin I., Ravaux I., Spire B. MANIF2000 cohort study group. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction. 2008, 103(11):1828-1836.
37. The Commission on Aids in Asia, 2008. Redefining AIDS in Asia: Crafting an effective response. Oxford University Press, Oxford, Available at http://wwwunaidsorg/en/media/unaids/contentassets/dataimport/pub/report/2008/20080326_report_commission_aids_enpdf.
38. Tran B.X., Ohinmaa A., Duong A.T., Do N.T., Nguyen L.T., Nguyen Q.C., Mills S., Jacobs P., Houston S. Changes in drug use are associated with health-related quality of life improvements among methadone maintenance patients with HIV/AIDS. Qual Life Res. 2011, (Epub ahead of print).
39. Tran B.X., Ohinmaa A., Duong A.T., Nhan D.T., Nguyen L.T., Mills S., Houston S., Jacobs P. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS Care 2011, (Epub ahead of print).
40. Tran B.X., Ohinmaa A., Nguyen L.T., Nguyen T.A., Nguyen T.H. Determinants of health-related quality of life in adults living with HIV in Vietnam. AIDS Care 2011.
41. TreeAge Software Inc., 2011. TreeAge Pro Version: 2011 Build-Id: 1.0.12.1-v20110119, Williamstown, MA.
42. University of Sheffield Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment. Pharmacoeconomics 2000, 17:443-444.
43. Vietnam Administration of HIV/AIDS Control, 2010. Report on the current situation of HIV infection in 2009. Hanoi: Vietnam http://www.vaac.gov.vn/Desktop.aspx/Noi-dung/Tinh-hinh-dich/Tinh_hinh_dich_nhiem_HIVAIDS_toan_quoc_nam_2009/.
44. Vietnam Ministry of Health, 2010. Cost of providing HIV care and treatment services in Vietnam. Hanoi.
45. Vu Van Tam, Do Duy Cuong, Cao Hong Tu, 2010. DOTARV: A randomised controlled trial to assess antiretroviral treatment strategies in relation to adherence, resistance and virological treatment failure. UNAIDS Seminar 06/04/2010 Available at Hanoi, Vietnam. http://wwwunaidsorgvn/sitee/images/stories/dotarv_presentation_hsph_6_april_2010_engpdf.
46. WHO, UNAIDS, UNICEF, 2010. Towards Universal Access: Setting Priority HIV/AIDS Interventions in the Health Sector. Progress Report 2010. Geneva.
47. Wolfe D., Carrieri M.P., Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet 2010, 376:355-366.
48. World Health Organization Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach-2006 rev 2006, Geneva, Switzerland.